18 results
8-K
EX-99.1
IDYA
Ideaya Biosciences Inc
7 May 24
IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results
6:04am
-sponsored Phase 2 trial of darovasertib in neoadjuvant UM accepted for an oral presentation at the 2024 American Society of Clinical Oncology (ASCO
8-K
EX-99.1
IDYA
Ideaya Biosciences Inc
20 Feb 24
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023
6:07am
as a Proffered Paper oral presentation at the 2023 European Society for Medical Oncology’s Congress (ESMO).
Expanded Phase 2 trial evaluating
424B5
diukanhchg9yi
19 Jan 24
Prospectus supplement for primary offering
5:15pm
8-K
EX-99.1
62hatc lvu8x
7 Nov 23
IDEAYA Biosciences, Inc. Reports Third Quarter 2023
6:01am
424B5
2qnjdzy
25 Oct 23
Prospectus supplement for primary offering
9:45pm
424B5
wfgc dopsk
24 Oct 23
Prospectus supplement for primary offering
5:26pm
8-K
dc432ftxpmym2t5nqau4
23 Oct 23
Other Events
8:09am
8-K
EX-99.1
fu1yw30sw1xvf5i
10 Aug 23
IDEAYA Biosciences, Inc. Reports Second Quarter 2023
6:01am
8-K
ms40pnqaxujbscj
20 Nov 19
Phase 1/2 Clinical Trial Data for IDE196 Presented at Society for Melanoma Research Congress
6:05am
8-K
EX-99.1
lwczhv
20 Nov 19
Phase 1/2 Clinical Trial Data for IDE196 Presented at Society for Melanoma Research Congress
6:05am
S-1
EX-10.2
s41oig1rrk3b3b4vcr
26 Apr 19
IPO registration
5:01pm
DRS/A
EX-10.2
lr4m8alr4w89s1zqm
4 Apr 19
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next